

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A method for treating psoriasis, the method comprising:
administering an effective amount of an inhibitor of integrin linked kinase (ILK) to a psoriatic lesion, wherein expression of ILK in psoriatic tissue correlates with severity of disease, and said ILK inhibitor is a small organic molecule that inhibits ILK activity.

2.- 14. (canceled)

15. (previously presented) The method according to claim 1, further comprising the step of administering a second therapy for psoriasis.

16. (previously presented) The method according to claim 15, wherein second therapy is selected from the group consisting of systemic therapy, ultraviolet light therapy, and topical therapy.

17. (previously presented) The method according to claim 15, wherein said second therapy is selected from the group consisting of antibiotics, antimicrobials, cyclosporine, methotrexate, hydroxyurea, NSAIDs, sulfasalazine, 6-thioguanine, acitretin, etretinate, isotretinoin; UVB phototherapy, photochemotherapy (PUVA), anthralin, calcipotriene, coal tar, corticosteroids, and tazarotene.

18. (previously presented) The method according to claim 1, wherein said ILK inhibitor is administered systemically.

19. (previously presented) The method according to claim 1, wherein said ILK inhibitor is administered dermally.

20. (previously presented) A method for treating psoriasis, the method comprising:
staining to determine the expression of integrin linked kinase in a psoriatic lesion, and where expression of ILK in said psoriatic lesion correlates with severity of disease;

USSN: 09/998,250

administering an effective amount of an inhibitor of integrin linked kinase (ILK), wherein said ILK inhibitor is a small organic molecule that inhibits ILK activity.

21-22. (canceled)